TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 174 filers reported holding TRAVERE THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 1.74 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $334,740 | -26.2% | 37,443 | +26.8% | 0.00% | – |
Q2 2023 | $453,412 | -18.1% | 29,519 | +19.9% | 0.00% | – |
Q1 2023 | $553,906 | +7.7% | 24,629 | +0.7% | 0.00% | – |
Q4 2022 | $514,394 | -96.2% | 24,460 | -95.5% | 0.00% | -100.0% |
Q3 2022 | $13,398,961 | +1.6% | 543,789 | -0.1% | 0.01% | 0.0% |
Q2 2022 | $13,188,219 | -5.9% | 544,293 | +0.0% | 0.01% | 0.0% |
Q1 2022 | $14,020,065 | -16.9% | 544,046 | -1.0% | 0.01% | -10.0% |
Q4 2021 | $16,871,000 | -1.4% | 549,488 | -22.2% | 0.01% | -28.6% |
Q3 2021 | $17,119,000 | +65.4% | 705,925 | -0.5% | 0.01% | +75.0% |
Q2 2021 | $10,351,000 | -82.1% | 709,502 | -69.3% | 0.01% | -84.0% |
Q1 2021 | $57,678,000 | -3.2% | 2,309,887 | +5.6% | 0.05% | -9.1% |
Q4 2020 | $59,603,000 | – | 2,186,830 | – | 0.06% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Lynx1 Capital Management LP | 411,680 | $10,609,000 | 9.85% |
VR Adviser, LLC | 1,994,997 | $51,411,000 | 8.33% |
Kynam Capital Management, LP | 870,918 | $22,444,000 | 7.28% |
GREAT POINT PARTNERS LLC | 1,010,000 | $26,028,000 | 6.29% |
Deep Track Capital, LP | 3,134,503 | $80,776,000 | 5.18% |
RA Capital Management | 4,922,941 | $126,864,000 | 2.77% |
ARMISTICE CAPITAL, LLC | 4,958,000 | $127,768,000 | 2.47% |
MPM BioImpact LLC | 277,950 | $7,163,000 | 1.92% |
Sofinnova Investments, Inc. | 658,249 | $16,963,000 | 1.29% |
Perceptive Advisors | 1,845,555 | $47,560,000 | 0.95% |